Observational study of chondrodermatitis nodularis helicis treated with methyl aminolevulinate photodynamic therapy - 14/12/17
, Lucia Turrión-Merino, MD b, Bibiana Pérez-García, MD, PhD b, David Saceda-Corralo, MD b, Antonio Harto-Castaño, MD, PhD b, Yolanda Gilaberte, MD, PhD aAbstract |
Background |
Therapies used to treat chondrodermatitis nodularis helicis (CNH), such as surgical excision, pressure relief, or topical steroids report varying degrees of success.
Objective |
We evaluated the response and safety of methyl aminolevulinate (MAL) photodynamic therapy (PDT) in CNH.
Methods |
This retrospective, observational study performed at the University Hospital Ramon y Cajal (Madrid, Spain) and Hospital San Jorge (Huesca, Spain) included all patients diagnosed with CNH and treated with MAL-PDT from 2008 to 2015. Treatment sites were prepared and irradiated as per the conventional MAL-PDT procedure.
Results |
Patients underwent a mean of 2.3 sessions with between-session intervals ranging from 15 days to 1 month. A complete response to PDT was observed in 33 patients (76.7%), who experienced pain relief and resolution of the inflammatory nodule. Lesion recurrence was recorded in 10 patients (23.3%) during the mean follow-up period of 20 months. Receiving ≥2 PDT sessions was significantly associated with a good response (26/28, 93% success rate, P = .003).
Limitations |
Some limitations of the study are the lack of an established between-session interval, the absence of evaluation of curettage effectiveness and the limited sample size.
Discussion |
The results support the view that PDT is a promising treatment approach for CNH.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Key words : chondrodermatitis nodularis helicis, methyl-aminolevulinate, photodynamic therapy, pressure relief, surgery, topical nitroglycerin
Abbreviations used : CNH, CRR, MAL, PDT
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
|
| Reprints not available from the authors. |
Vol 76 - N° 6
P. 1103-1108 - juin 2017 Retour au numéro
Article précédent
- Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
- Kim Papp, Herve Bachelez, Antonio Costanzo, Peter Foley, Melinda Gooderham, Primal Kaur, Joanna Narbutt, Sandra Philipp, Lynda Spelman, Jolanta Weglowska, Nan Zhang, Bruce Strober
- Erosive pustular dermatosis of the scalp: Clinical, trichoscopic, and histopathologic features of 20 cases
- Michela Starace, Camilla Loi, Francesca Bruni, Aurora Alessandrini, Cosimo Misciali, Annalisa Patrizi, Bianca Maria Piraccini
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?